Psychological continuum of elderly hypertensive patients with metabolic syndrome receiving chronotherapy with a fixed-dose combination of amlodipine, lisinopril and rosuvastatin

Aim. To study the psychological continuum of elderly hypertensive patients with metabolic syndrome (MS) receiving chronotherapy with a fixed-dose combination of amlodipine, lisinopril and rosuvastatin.

Material and  methods. In a  clinical setting, 63 hypertensive  patients with MS aged 60-74 years (experimental group) received chronotherapy with fixed-dose combination of amlodipine, lisinopril and rosuvastatin (Ekvamer®) at a dose of 5/10/10 mg in the evening (8 pm). The control group of hypertensive patients with MS aged 60-74 years old (n=58) received Ekvamer® in the morning (conventional therapy) at the same dosage.

Results. With fixed-dose combination of amlodipine, lisinopril and rosuvastatin, the severity of psychological continuum abnormalities significantly decreases after 1 year in the chronotherapy regimen (evening intake) than with morning intake with an equivalent dosage of 5/10/10 mg per day in both cases. The dynamics of cognitive impairments in hypertensive patients aged 60-74 years with MS using chronotherapy regimen is characterized by a significant increase  in  the  mean MMSE score from the initial 17,8±0,3 to 23,5±0,4 points (p±0,001) vs 16,9±0,3 to 20,4±0,4 points (p<0,001) when taking the drug in the morning. Situational anxiety decreased from 40,0±2,2 to 30,6±1,8 points (p<0,05) vs 40,8±2,5 to 33,5±1,9 points (p<0,05), personal anxiety from 48,8±2,0 to 26,4±1,9 (p<0,001) vs from 44,9±1,9 to 30,7±1,7 (p<0,01) points, respectively. Depressive disorders slightly decreased with chronotherapy (14,1%) vs 7,7% than with the conventional scheme, but despite this, they corresponded to depressive spectrum disorders in both groups.

Conclusion. The results obtained indicate a greater efficiency of chronotherapy than the conventional use of fixed-dose combination of amlodipine, lisinopril and rosuvastatin in hypertensive patients with MS.

1. Sergeeva VA. Principles of antihypertensive therapy in metabolic syndrome. Clinical Medicine. 2013;91(6):4-8. (In Russ.)

2. Zhang J, Wang WL. Risk factors of metabolic syndrome after liver transplantation. Hepatobiliary Pancreat Dis. Int. 2015;14(6):582-7. doi:10.1016/s1499-3872(15)60037-6.

3. Ibrahim MS. Risk models and scores for metabolic syndrome: systematic review protocol. BMJ OPEN. 2019;9(9):e027326. doi:10.1136/bmjopen-2018-027326.

4. Satybaldieva AD. Features of the course of essential arterial hypertension in the elderly and senile age. Bulletin of the Almaty State Institute of Advanced Training of Doctors. 2017;1:22-8. (In Russ.)

5. Toshima T. Risk factors for the metabolic syndrome components of hypertension, diabetes mellitus, and dyslipidemia after living donor liver transplantation. HPB (Oxford). 2019;1365(182):30695-701. doi:10.1016/j.hpb.2019.08.008.

6. World Medical Association, Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191-4. doi:10.1001/jama.2013.281053.

7. Gasparyan AYu. Features of metabolic syndrome in elderly and senile people, residents of besieged Leningrad. Sistemnye gipertenzii. 2008;5;263-9. (In Russ.)

8. Dzherieva IS. Association between depression and metabolic syndrome. Clinical Medicine. 2015;93(1):62-5. (In Russ.)

9. Mikhailovskaya NS. Relationship of anxiety and depressive disorders with the course of coronary heart disease, comorbid with metabolic syndrome. Zaporozhye Medical Journal. 2015;5:23-7. (In Russ.)

10. Ostroumova OD. Effect of drugs with anticholinergic activity on the cognitive functions of patients 80 years and older with essential arterial hypertension. Arterial Hypertension. 2019;25(3):246-57. (In Russ.)

11. Ascaso JF. Prevalence of metabolic syndrome and cardiovascular disease in a hypertriglyceridemic population. Eur. J. Intern Med. 2011;22(2):177-81. doi:10.1016/j.ejim.2010.12.011.

12. Recommendations of experts of the All-Russian Scientific Society of Cardiology on the diagnosis and treatment of metabolic syndrome (second revision). Practical Medicine. 2010;44(5):81-101. (In Russ.)

13. National recommendations of experts of the All-Russian Scientific Society of Cardiology on the diagnosis and treatment of arterial hypertension (4th revision). Systemic hypertension. 2010;3:5-26. (In Russ.)

14. Andryushchenko AV, Drobizhev MYu, Dobrovolsky AV. Comparative evaluation of the CESD, BDI and HADS(D) scale in the diagnosis of depression in General medical practice. Journal of Neurology and Psychiatry named after S. S. Korsakov. 2003;5:11-8. (In Russ.)

15. Zhang J, Liu N, Yang Ch. Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease. Panminerra Med. 2019;61(4):439-43. doi:10.23736/S0031-0808.18.034.